Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Qiagen, Ortho Clinical Diagnostics, MicroGen Diagnostics, and More

NEW YORK – Qiagen said this week it has been chosen to be included in Germany's DAX (Deutscher Aktienindex) stock market index as part of an expansion of the index to the 40 largest companies based on market capitalization. Qiagen will join the index on Sept. 20, and will remain in TecDAX which comprises the 30 largest German technology sector companies. The company, which is on track for more than $2 billion in sales in 2021, also has its shares listed on the New York Stock Exchange.

Ortho Clinical Diagnostics this week priced a previously announced underwritten secondary offering of 22 million ordinary shares held by a selling shareholder affiliated with Carlyle Group, at a price of $17.50 per ordinary share. The selling shareholder granted the underwriters an option to purchase up to 3.3 million additional ordinary shares within 30 days of the pricing of the offering.

Goldman Sachs and JP Morgan Securities are acting as the joint book-running managers and as representatives of the underwriters for the offering, which is expected to close Sept. 14. Ortho is not selling any ordinary shares in the offering, and will not receive any of the proceeds from it.

MicroGen Diagnostics announced this week that it has resolved a dispute with Advent Health about COVID-19 testing services provided in May 2020. Advent ended its testing contract with MicroGenDx due to concerns about timing and reliability of testing services. MicroGenDx claimed the federal government’s sequestering of necessary supplies interfered with delivery of services and said its tests were reliable.

BelHealth Investment Partners said this week that it has completed the sale of assets of the international division of General Genetics, which trades as EasyDNA, to Genetic Technologies of Australia through a combination of cash and stock. Genetic Technologies said in July that it planned to acquire direct-to-consumer DNA testing provider EasyDNA for $4 million.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.